Shanghai Kehua Bio-Engineering Co Ltd (002022) fair value: what the stock is really worth
We calculate from audited financials what Shanghai Kehua Bio-Engineering Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Shanghai Kehua Bio-Engineering Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ¥4.58 – ¥17.72 · fair‑value band ¥0.5200 – ¥0.9800 · the ¥6.17 price screens above the ¥0.7800 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally.
Show more
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. Further, it provides instrument products, including biochemical diagnostics, immunological diagnostics, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry, advancing towards automation, digitization, and intelligence. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.
Stock analysis
Shanghai Kehua Bio-Engineering Co Ltd (002022) currently trades at ¥6.17, while our model-based Fair Value estimate is ¥0.7800, implying the stock looks roughly 691.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.
Scenario range: ¥0.5200 (bear) to ¥0.9800 (bull), the price of ¥6.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shanghai Kehua Bio-Engineering Co Ltd reported revenue of 1.6B CNY in FY2025 versus 4.9B CNY in FY2021, a compound −23.7%/yr. Reported net income was −732M CNY in FY2025.
Key figures
Market cap 3.2B CNY (≈ $475M) · P/S ratio 1.60 · EPS (TTM) ¥−1.41 · Dividend yield 0.6% · Net margin −44.6% · Return on equity −25.0% · Return on assets (EBIT) 4.6% · Operating margin −8.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −87%, 002022 screens richer than that median.
Fair Value models
Bear ¥0.5200Fair Value ¥0.7800Bull ¥0.9800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.9%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
32.7% (2020) → −20.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Shanghai Kehua Bio-Engineering Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−86% · Bottom 25%
Profitability
Return on assets−9% · Below median
Net margin (TTM)−44% · Bottom 25%
Operating margin (TTM)−9% · Below median
Growth and dividend
Revenue growth2% · Below median
Dividend yield (TTM)0.6% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.15× · Cheapest 25%
P/S (TTM)0.24× · Cheapest 25%
PEG3.23× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)10· sector 32
PAST (return on equity)0· sector 7
HEALTH (low debt)99· sector 97
DIVIDEND (yield)12· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Kehua Bio-Engineering Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002022
Frequently asked questions
Is Shanghai Kehua Bio-Engineering Co Ltd (002022) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥0.7800 versus a price of ¥6.17, about −87% upside (overvalued).
What is the fair value of 002022?
Our model-based fair value for Shanghai Kehua Bio-Engineering Co Ltd is ¥0.7800 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥6.17.
What is the quality score of 002022?
Shanghai Kehua Bio-Engineering Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Our model-based price target is the fair value of ¥0.7800 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario ¥0.5200, optimistic scenario ¥0.9800. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Kehua Bio-Engineering Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.7800, about −87% upside versus a price of ¥6.17 (overvalued). Cautious scenario ¥0.5200, optimistic scenario ¥0.9800. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Shanghai Kehua Bio-Engineering Co Ltd reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Sep 13, 2026).
Does Shanghai Kehua Bio-Engineering Co Ltd pay a dividend?
Shanghai Kehua Bio-Engineering Co Ltd currently shows a dividend yield of about 0.59% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Kehua Bio-Engineering Co Ltd it is ¥0.7800 per share (as of Sep 13, 2026), against a price of ¥6.17. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Kehua Bio-Engineering Co Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 002022 trades above its calculated fair value: price ¥6.17, fair value ¥0.7800, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002022?
No. The price is what the market pays today (¥6.17); the fair value is what the company's own numbers justify (¥0.7800). For Shanghai Kehua Bio-Engineering Co Ltd the two are ¥5.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Kehua Bio-Engineering Co Ltd worth?
The market values Shanghai Kehua Bio-Engineering Co Ltd at about 3.2B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥6.17; our models calculate a fair value of ¥0.7800 per share.
What do the bullish and bearish scenarios say about 002022?
Our models span a range for Shanghai Kehua Bio-Engineering Co Ltd: cautious scenario ¥0.5200, base ¥0.7800, optimistic ¥0.9800 per share (as of Sep 13, 2026, price ¥6.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 002022?
The PEG ratio of Shanghai Kehua Bio-Engineering Co Ltd is 3.23 (P/E divided by earnings growth, as of Sep 13, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Balance-sheet figures for Shanghai Kehua Bio-Engineering Co Ltd (as of Sep 13, 2026): return on equity −25.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 002022 from its 52-week high?
Shanghai Kehua Bio-Engineering Co Ltd trades at ¥6.17, about 27% below its 52-week high of ¥8.45 and 24% above the low of ¥4.98 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.7800 is for.
Which stocks are comparable to Shanghai Kehua Bio-Engineering Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Kehua Bio-Engineering Co Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price ¥6.17, calculated fair value ¥0.7800 (−87%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002022 calculated?
We run Shanghai Kehua Bio-Engineering Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.7800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Shanghai Kehua Bio-Engineering Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The closing price on Sep 21, 2026 was ¥6.17. Our model-based fair value is ¥0.7800, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Kehua Bio-Engineering Co Ltd right now?
The price sits above even our optimistic bull case (¥0.9800). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.5200 to ¥0.9800) leaves room in how you read the outcome.
Key figures of Shanghai Kehua Bio-Engineering Co Ltd
How large is the market capitalisation of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The market capitalisation of Shanghai Kehua Bio-Engineering Co Ltd is 3.2B CNY (≈ $475M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The price-to-sales ratio of Shanghai Kehua Bio-Engineering Co Ltd is 1.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Earnings per share at Shanghai Kehua Bio-Engineering Co Ltd are ¥−1.41. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The dividend yield of Shanghai Kehua Bio-Engineering Co Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The net margin of Shanghai Kehua Bio-Engineering Co Ltd is −44.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The return on equity (ROE) of Shanghai Kehua Bio-Engineering Co Ltd is −25.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
On an EBIT basis the return on assets of Shanghai Kehua Bio-Engineering Co Ltd is 4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Kehua Bio-Engineering Co Ltd (002022)?
The operating margin of Shanghai Kehua Bio-Engineering Co Ltd is −8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Revenue at Shanghai Kehua Bio-Engineering Co Ltd is growing +1.9% versus a year earlier (3y avg −38.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Kehua Bio-Engineering Co Ltd (002022)?
Earnings per share at Shanghai Kehua Bio-Engineering Co Ltd are growing +146% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai Kehua Bio-Engineering Co Ltd (002022) generate?
The free cash flow of Shanghai Kehua Bio-Engineering Co Ltd is −117M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Shanghai Kehua Bio-Engineering Co Ltd (002022) hold?
Shanghai Kehua Bio-Engineering Co Ltd holds more cash than debt, 455M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shanghai Kehua Bio-Engineering Co Ltd in the live analysis
One click puts Shanghai Kehua Bio-Engineering Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
